Хлебные крошки
- Главная
-
Аналитика
-
Акции
Акции внутренные
Vertex, Inc. VERX
$20.05
+$0.3 (1.52%)
На 18:02, 12 мая 2023
Ранг: 2
Ключевые показатели
-
Marketcap
3198857633.00000000
-
week52high
22.98
-
week52low
9.44
-
Revenue
491624000
-
P/E TTM
-246
-
Beta
0.59761200
-
EPS
-0.08000000
-
Last Dividend
0.00000000
-
Next Earnings Date
10 мая 2023 г. в 12:30
Описание компании
Vertex, Inc. provides tax technology solutions for corporations in retail, communication, leasing, and manufacturing industries in the United States and internationally. It offers tax determination, compliance and reporting, tax data management, document management, pre-built integration, and industry-specific solutions. The company sells its software products through software license and software as a service subscriptions. It also provides implementation and training services in connection with its software license and cloud subscriptions, transaction tax returns outsourcing, and other tax-related services. Vertex, Inc. was founded in 1978 and is headquartered in King of Prussia, Pennsylvania.
Рекомендации
аналитиков
Рекомендации аналитиков
| Grading company | New grade | Previous grade | Recommendation date |
|---|---|---|---|
| Morgan Stanley | Underweight | Underweight | 14 июл 2022 г. |
| Jefferies | Buy | Buy | 23 мая 2022 г. |
| Morgan Stanley | Underweight | Underweight | 11 мая 2022 г. |
| Needham | Buy | Buy | 10 мар 2022 г. |
| JMP Securities | Market Outperform | Market Outperform | 10 мар 2022 г. |
| Citigroup | Neutral | 01 сент 2022 г. | |
| Goldman Sachs | Buy | 21 окт 2022 г. | |
| BMO Capital | Market Perform | Market Perform | 10 ноя 2022 г. |
| Jefferies | Hold | Buy | 05 янв 2023 г. |
| Morgan Stanley | Underweight | Underweight | 19 дек 2022 г. |
Свежие комментарии
Свежие комментарии
Оставьте свой голос
Оставьте свой голос
Анонимное голосование
Будет ли рост российского рынка к концу года?
-
Да
87% -
Нет
12%
Проголосовал 8 человек
Новостная лента
компании
Insider Summary
Insider Summary
| Reporting Name | Acquistion/Disposition | Owned | Transacted | Transaction Date |
|---|---|---|---|---|
| SCHWAB JOHN R | D | 471473 | 7439 | 14 дек 2022 г. |
| SCHWAB JOHN R | D | 5579 | 7439 | 14 дек 2022 г. |
| SCHWAB JOHN R | A | 13018 | 7439 | 14 дек 2022 г. |
| DeStefano David | D | 267660 | 9089 | 14 дек 2022 г. |
| DeStefano David | D | 276749 | 30000 | 13 дек 2022 г. |
| DeStefano David | D | 306749 | 9631 | 12 дек 2022 г. |
| Robert Kevin L | D | 23615 | 7894 | 06 дек 2022 г. |
| SCHWAB JOHN R | D | 478912 | 899 | 05 дек 2022 г. |
| SCHWAB JOHN R | D | 5579 | 899 | 05 дек 2022 г. |
| SCHWAB JOHN R | A | 6478 | 899 | 05 дек 2022 г. |
Новостная лента
Will Vertex (VERX) Beat Estimates Again in Its Next Earnings Report?
Zacks Investment Research
06 февр 2023 г. в 13:33
Vertex (VERX) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.
Vertex: Strong Market Position In The Enterprise Segment
Seeking Alpha
23 янв 2023 г. в 07:44
Taxes are unavoidable and they are getting increasingly hard to comply with. Vertex has a strong position in the enterprise segment.
Down -20.32% in 4 Weeks, Here's Why You Should You Buy the Dip in Vertex (VERX)
Zacks Investment Research
20 янв 2023 г. в 11:18
Vertex (VERX) has become technically an oversold stock now, which implies exhaustion of the heavy selling pressure on it. This, combined with strong agreement among Wall Street analysts in revising earnings estimates higher, indicates a potential trend reversal for the stock in the near term.
Here's Why Vertex (VERX) Looks Ripe for Bottom Fishing
Zacks Investment Research
13 янв 2023 г. в 11:18
Vertex (VERX) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.
Biotech stocks: Vertex looks bullish on ‘rapidly-growing CF business,' analyst says
Yahoo Finance
05 янв 2023 г. в 15:49
Bank of America Global Research Sr. Pharma Analyst Geoff Meacham joins Yahoo Finance Live anchors Akiko Fujita and Rachelle Akuffo to discuss China's COVID-19 chaos, the pharma space, biotech stocks, and the outlook for biopharma.